Ocular Therapeutix reports Q3 EPS (38c), consensus (35c)

Reports Q3 revenue $14.5M, consensus $14.57M. “At Ocular Therapeutix (OCUL), we are courageous, bold, opportunistic, and driven by a refusal to accept the status quo. We think differently about what is possible by designing creative, de-risked clinical programs that are tightly aligned with the FDA, while advancing patient care,” said Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer of Ocular Therapeutix. “At our September Investor Day, we presented our HELIOS program for AXPAXLI in diabetic retinopathy which embodies this philosophy: we’ve designed a novel ordinal DRSS endpoint that reflects real-world treatment goals, potentially increases the probability of success, and is agreed to by the FDA through our Special Protocol Assessment (SPA) agreement for HELIOS-2. We also shared that the true market opportunity for anti-VEGFs may extend far beyond today’s approximately $15 billion annual market. The opportunity for expansion could be driven by the millions of wet AMD patients who discontinue treatment or are undertreated because current options are not sustainable. Moreover, we also see opportunity for expansion in NPDR, a disease three times as prevalent as wet AMD with no standard-of-care in use today, and DME. Across every dimension, from trial design and patient selection to execution and product profile, we embody our philosophy of being courageous, bold and opportunistic.”